Meeting
2022 ASCO Annual Meeting
Codon-specific KRAS mutations predict overall survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
Authors
Joris van de Haar
Netherlands Cancer Institute (Netherlands ), Amsterdam, Netherlands
Joris van de Haar , Xuhui Ma , Salo N. Ooft , Pim W. van der Helm , Louisa Rose Hoes , Sara Mainardi , Lodewyk F.A. Wessels , Emile E. Voest
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Advanced Disease
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3593)
DOI
10.1200/JCO.2022.40.16_suppl.3593
Abstract #
3593
Poster Bd #
387
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
Survival impact on regorafenib (REG) and trifluridine/tipiracil hydrochloride (FTD/TPI) for patients with metastatic colorectal cancer: Single institutional experience.
First Author: Keigo Chida
Poster
2018 Gastrointestinal Cancers Symposium
Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study.
First Author: Guillem Argiles
Poster
2016 ASCO Annual Meeting
MAVERICC, a phase II study of mFOLFOX6-bevacizumab (BV) vs FOLFIRI-BV as first-line (1L) chemotherapy (CT) in patients (pts) with metastatic colorectal cancer (mCRC): Outcomes by tumor location and KRAS status.
First Author: Heinz-Josef Lenz
Poster
2016 Gastrointestinal Cancers Symposium
Phase III RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups.
First Author: Atsushi Ohtsu